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WHO = World Health Organization
1 
1. INTRODUCTION 
 
1.1. CRF and CRF receptors  
Corticotropin-releasing hormone (CRH) or corticotropin-releasing factor (CRF) is a 41 
amino acid neuropeptide. It is also known as corticoliberin, because it is the major 
neurohormone that stimulates the release of adrenocorticotropic hormone (ACTH) or 
corticotropin, along with the synergistic arginin-vasopressin (AVP), both being released from 
the paraventricular nucleus (PVN) of the hypothalamus [1-2]. CRF is also an important 
extrahypothalamic neurotransmitter that is released from the medulla oblongata and the 
central nucleus of the amygdala (CeA) [3-4]. Thus, CRF is expressed mainly in the central 
nervous system (CNS), but it is also found in the periphery: in the gastrointestinal (GI) tract, 
skin, and adrenal gland [3-4]. The main role of CRF is to mediate the neuroendocrine, 
autonomic and behavioral stress responses [3-4]. The neuroendocrine stress response is 
represented by the activation of the hypothalamic-pituitary adrenal (HPA) axis that is 
mediated by CRF released from the PVN in order to stimulate the release of ACTH from the 
anterior pituitary and the subsequent release of glucocorticoids (corticosterone in rodents, 
cortisol in humans) from the adrenal cortex [3-4]. The autonomic stress response is 
represented by the activation of the sympathetic nervous system (SNS) that is mediated by 
CRF released from the medulla oblongata which, in turn, stimulates the locus coeruleus (LC) 
noradrenaline (NA) system, and eventually the release of adrenaline from the adrenal medulla 
[3-4]. The behavioral stress response is manifested by increased locomotor activity in a 
familiar environment, decreased locomotor activity in an unfamiliar environment, decreased 
food and water intake, decreased social and sexual activity which are mediated among others 
by amygdalar CRF [3-4] (Figure 1). 
The actions of CRF are mediated via two different CRF receptors (CRFRs), CRFR1 
and CRFR2, which are two proteins of 415 and 397-437 amino acids, respectively [5-6]. 
CRFRs belong to the class B subtype of G protein–coupled receptor (GPCR) superfamily and 
they are produced from distinct genes and have several splice variants expressed on the 
surface of various central and peripheral tissues [7]. CRFR1 has α and β isoforms in addition 
to subtypes designated c-h, which have been detected in rodent and human tissues [8]. CRFR2 
is expressed in three functional subtypes, α, β, and γ [8]. CRFR2α and CRFR2β have been 
detected in rodents, primates and humans, but CRFR2γ has only been reported in humans [8]. 
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Figure 1. The role of the hypothalamic (A) and extrahypothalamic CRF (B) [9] 
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Both CRFRs are found in the CNS and the periphery, although CRFR1 is expressed 
more abundantly in the CNS, whereas CRFR2 is more dominant in the periphery [10].  
In the CNS CRFR1 is distributed throughout the cerebral cortex, cerebellum, olfactory bulb, 
medial septum, hippocampus, amygdala, and anterior pituitary [11]. CRFR2 is limited 
centrally to subcortical regions, such as the lateral septum, hippocampus, amygdala, 
hypothalamus, and posterior pituitary [11]. In addition, both CRFRs are expressed in the 
ventral and dorsal striatum [11]. Initially, it was presumed that CRFR1 and CRFR2 promote 
antagonistic effects in the CNS, since activation of CRFR1 induced activation of the HPA 
axis, anxiety, depression, and locomotor hyperactivity (at least in a familial environment), 
whereas activation of CRFR2 produced anxiolytic, antidepressant, and locomotor suppessive 
effects [1, 3-4] (Figure 2). Recently, it was proposed that the role of CRFR1 and CRFR2 in 
the stress response is not a matter of simple dualism, but it depends upon the brain regions 
and neuron populations being activated [12-13] (Figure 3). 
 
 
 
Figure 2. The role of CRFR1 and CRFR2 in the stress response (the classic theory) [14] 
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A. 
 
B.
 
Figure 3. The role of CRFR1 and CRFR2 in anxiety and depression (the new theory) [13] 
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1.2. CRF receptor agonists 
Since CRF has been isolated [1], a new family of CRF-like peptides, termed urocortins 
were discovered. The name urocortin derives from the frog analogue of CRF urotensin (URO) 
and CRF or corticoliberin itself [15]. Thus, today the mammalian family of CRF-related 
peptides consists of three ligands: urocortin I (UCN I) [16], urocortin II (UCN II) [17], and 
urocortin III (UCN III), two receptors: CRFR1 and CRFR2, and one binding protein: CRF-BP 
[15]. In humans, UCN II is also known as stresscopin-related peptide (SRP), while UCN III is 
known as stresscopin (SCP) [18]. 
The urocortins have similar chemical structures, but different anatomical distribution, 
pharmacological properties and physiological functions, when comapred to CRF [19-20] 
(Figure 4). 
A. 
 
B. 
 
Figure 4. The chemical structure (A) and intracellular signalization (B) of CRFR agonists 
[15] 
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 As aforementioned, CRF is a 41 aminoacid neuropeptide isolated first from ovine 
brain that is expressed predominently in the PVN and the CeA, but it was also found in the 
periphery: the GI tract, skin, and adrenal gland [21-23]. CRF fibers were shown in the internal 
layer of the median eminence, lateral septum, central amygdala, bed nucleus of the stria 
terminalis (BNST), raphe nuclei and spinal cord [21-23]. In contrast, UCN I is a 40 amino 
acid neuropeptide that was identified for the first time in rat midbrain [16]. It is expressed 
prominently in the Edinger–Westphal nucleus (EWN), rostroventral midbrain, supraoptic 
nucleus of the hypothalamus and superior lateral olive [24-28]. Dense UCN I fibers were 
found in the the internal layer of the median eminence, lateral septum, dorsal raphe nucleus 
and spinal cord, with scattered fibers in the hypothalamus, hippocampus, cerebral cortex, and 
posterior pituitary [21, 23-24, 27-28]. In the periphery UCN I was shown in the GI tract, 
testis, cardiac myocytes, thymus, skin, and spleen [19-20]. UCN II is a 38 amino acid 
neuropeptide that was cloned from the mouse brain and named SRP in humans [17]. UCN II 
is expressed in the PVN, arcuate nucleus of the hypothalamus and LC [17, 27, 29]. The 
terminals of the UCN II fibers are unknown, since no reliable UCN II immunohistochemistry 
has been performed yet. In the periphery UCN II was found in the heart, blood cells, and 
adrenal gland [19-20]. UCN III is another 38 amino acid neuropeptide that was cloned from 
the mouse brain and named SCP in humans [18]. UCN III is expressed in the forebrain 
regions, the preoptic nucleus and perifornical region of the hypothalamus and the medial 
nucleus of the amygdala [18, 30]. UCN III fiber terminals were found in the ventromedial 
hypothalamus, lateral septum, BNST and the medial nucleus of the amygdala [18, 30]. In the 
periphery UCN III was found in the GI tract and pancreas [19-20] (Figure 5). 
CRF has tenfold higher affinity for CRFR1 than for CRFR2, while UCN I show equal 
affinity for both CRFRs. In contrast, UCN II and UCN III have 1000 fold higher affinity for 
CRFR2, therefore they are considered selective agonists of CRFR2 [15]. In addition, CRF and 
UCN I can be found attached to CRF-BP [20, 31]. CRF-BP is a 37-kDa N-linked glycoprotein 
expressed in the brain and pituitary of rodents, primates and humans [7, 32]. In rats CRF-BP 
has been demonstrated to block CRF-induced ACTH secretion from rat anterior pituitary cells 
[7, 32]. In humans, CRF-BP was detected in the liver and in the circulation [7, 32].  
It was suggested that CRF-BP may inhibit the activation of the HPA axis under different 
conditions, such as pregnancy [7, 32]. CRF-BP is also located in brain regions which are not 
associated with CRF activity, locations which suggest that it may also have CRF-independent 
functions, such as feeding and cognition [7, 32] (Figure 6). 
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Figure 5. The anatomical distribution of the CRFR agonists (A) and CRFRs (B) [33] 
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Figure 6. The pharmacological properties and intracellular signalization of the CRFR 
agonists 
Figure 7. The physiological effects of the CRFR agonists [15] 
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Central administration of CRF and UCN I induced activation of the HPA axis, 
anxiety-like and depression-like behavior [1, 4, 16], while central administration of UCN II 
and UCN III produced anxiolytic and antidepressant actions [34-37]. Accordingly, activation 
of the CRFR1, expressed predominantly in the cerebral cortex and the anterior pituitary, is 
believed to initiate the neuroendocrine, autonomic and behavioral reactions to stress [4, 10, 
33], whereas activation of the CRFR2, expressed centrally in hypothalamus and the lateral 
septum, is thought to terminate these stress responses [4, 10, 33] (Figure 7). Nevertheless, the 
exact role of CRFR1 and CRFR2 in the stress response and stress-related behavior is still 
under debate [19-20], because studies in mice and rats led to contradictory findings [38-42]  
(Figure 8). 
A. 
 
B. 
 
Figure 8. The role of CRFR1 and CRFR2 in the stress-related behavior [15] 
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1.3. CRF receptor antagonists 
In order to determine the role of CRF in the regulation of the neuroendocrine, 
autonomic and behavioral stress responses, non-selective CRFR antagonists were developed. 
The first CRF antagonist synthesized was -helical CRF 9-41, the second was D-Phe CRF; 
both being peptidic and competitive CRFR antagonists [43-45]. Both anatgonists were 
derived from CRF and blocked efficiently the CRF- and stress-induced ACTH secretion and 
locomotor activation [43-45]. The third CRFR antagonist synthesized, astressin was shown to 
be particularly potent at inhibiting the HPA axis [46]. This antagonist was also proved to 
reduce the CRF- and stress-induced anxiogenic-like behavior, but it failed to reverse the CRF 
and stress-induced locomotor hyperactivity [46].  
To investigate the exact role of CRFR1 and CRFR2 in the stress responses, selective 
CRFR antagonists were also developed (Figure 9).  The first selective CRFR1 antagonist was 
CP-154,526 that was followed by its structural analogue antalarmin [47-51]. These are non-
peptidic and competitive CRFR1 antagonists, which are able to penetrate the blood-brain 
barrier and inhibit the stress-induced neuroendocrine and behavioral response [47-51]. 
Therefore it was suggested that selective CRFR1 antagonists could be used as future therapy 
in stress-related psychiatric diseases, such as anxiety, depression, post-traumatic stress 
disorder (PTSD) and panic disorder [33]. The first selective antagonists of CRFR2 were 
antisauvagine-30 and astressin2B, derived from the frog analogue sauvagine and the non-
selective CRF antagonist astressin, respectively [43, 52-55]. These antagonists have peptidic 
structure, hence they are not able to penetrate the blood-brain barrier. Therefore, they are 
administered preferentially in the periphery, for example in order to elucidate the role of 
CRFRs in colonic transit and gastric emyptying [43, 52-55]. The use of selective CRF 
antagonists concluded that CRFR1 increases colonic transit, whereas CRFR2 decreases 
gastric empyting, thus it was suggested that selective CRFR2 antagonists could be used as 
potential therapeutics in stress-related GI disorders, such as in inflammatory bowel diseases 
(IBD) and irritable bowel syndrome (IBS) [52] (Figure 10). 
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Figure 9. The pharmacological actions of the non-selective and selective CRFR antagonists 
[56] 
 
 
Figure 10. The therapeutical actions of the selective CRFR antagonists [57] 
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1.4. Nicotine and nicotine receptors 
 Besides the regulation of the stress responses, CRF has been implicated in nicotine 
addiction based on several lines of evidence [58-59]. First, acute administration of nicotine, 
like any other stressor, induces a dose-dependent activation of the HPA axis that is initiated 
by hypothalamic CRF [58-59]. Second, nicotine withdrawal syndrome resembles the 
behavioral stress response that is mediated by extrahypothalamic CRF [58-59]. Third, 
exposure to stressors is one of the leading causes of nicotine relapse that implies the 
activation of the CRF systems [58-59]. Finally, both CRF receptors seem to participate in the 
acute, chronic and withdrawal actions of nicotine [60-64]. The basis of nicotine addiction is a 
combination of positive reinforcement, given by the rewarding, positive effects of nicotine, 
and negative reinforcement, maintained by the avoidance of the aversive, negative effects of 
nicotine withdrawal [65] (Figure 11). 
 
 
 
Figure 11. The basis of nicotine addiction 
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Nicotine is the main psychoactive component of tobacco that causes addiction [66]. 
Nicotine addiction leads to the harmful habit of smoking that has high morbidity and 
mortality throughout the world [66]. It is the most frequent type of substance dependence 
from all substances of abuse resulting in the loss of more than 7 million people per year 
worldwide [66]. According to the World Health Organization (WHO), in 2018 more than 6 
million people died due to first hand smoking, while 1 million were non-smokers, being 
exposed to second-hand smoking [66]. Nicotine is an alkaloid that is naturally extracted from 
tobacco; there is approximately 1 mg of nicotine in every cigarette produced from tobacco 
[66]. During cigarette smoking nicotine enters the lungs, it is absorbed into the bloodstream 
and reaches the brain in about 8 seconds [66]. Besides its psychostimulant effect, nicotine 
induces increase of the heart rate, arterial and venous constriction via release of adrenaline, 
but also contraction of the skeletal and smooth muscles via release of acetylcholine [66].  
The actions of nicotine are mediated by nicotinic acetylcholine receptors (nAChRs) 
that are considered ligand-gated ion channels composed of pentameric combinations of α and 
β subunits, since normally they respond to acetycholine [65]. Binding to these pentametric 
ligand-gated ion channels, nicotine causes a rotation of the receptor that results in the opening 
of the integral cation channel [65]. Activation of nAChRs leads to increased permeability to 
both Na
+
 and Ca
2+
 resulting in local depolarization, inducing the release of various 
neurotransmitters [66-67]. Based on their primary sites of expression, nAChRs are classified 
into two subtypes: muscle-type nicotinic receptors found in neuromuscular junctions and 
neuronal-type nicotinic receptors found on neuronal bodies and nerve terminals [65].  
In the brain there are nine isoforms of the neuronal α-subunit (α2- α10) and three isoform of 
β-subunit (β2- β4). These are combinations of two α- and three β-, or five α7-subunits with 
different distinct pharmacological properties, as regards nicotine sensitivity and rate of 
desensitization [66-67]. The most abundant neuronal nAChRs are α4β2, α3β4 and α7 located 
both pre- and postsynaptically where they can influence the release of other neurotransmitters, 
such as dopamine, glutamate and gamma-aminobutyric acid (GABA) [66-67] (Figure 12). 
 A better understanding of the mechanisms of nicotine addiction has led to the 
development of new drugs, such as varenicline (a partial agonist of the α4β2 nAChR) and 
bupropion (an antagonist of nAChRs), which block the negative and positive reinforcement, 
respectively [65]. 
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A. 
 
 B. 
 
Figure 12. The anatomical distribution (A) and chemical structure (B) of nAChRs [68] 
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2. AIM OF STUDY 
 
 Besides different types of nAChRs, CRFR1 and CRFR2 can also be potential targets 
in the therapy of nicotine addiction. Based on the initial concept that CRFR1 and CRFR2 
mediate mainly antagonistic effects in the CNS, there are two potential ways to approach the 
therapy of nicotine addiction: to use selective antagonists of CRFR1, such as antalarmin or to 
use selective agonists of CRFR2, such as UCN II and UCN III [3-4].  
Previous studies have already indicated that blocking CRFR1 would reduce some of 
the affective symptoms (the dysphoria and the reward deficit) [60, 62-63, 125], whereas 
blocking CRFR2 would reverse some of the somatic symptoms (the excessive food intake and 
the increased body weight) of nicotine withdrawal syndrome [64]. Other studies have also 
indicated that activating CRFR2 would reduce the anxiety- or depression-like behavior 
observed during alcohol withdrawal [126-127]. 
The aim of the present study was to investigate the potential therapeutical actions of 
selective CRFR1 and CRFR2 antagonists and selective CRFR2 agonists in rodents exposed to 
chronic nicotine treatment and consequent acute nicotine withdrawal. On the one hand, the 
effects of antalarmin and astressin 2B on the alterations of the dorsal and ventral striatal 
dopamine release and the vertical and horizontal locomotor activity were examined in 
nicotine-treated rats. On the other hand, the impacts of UCN II and UCN III upon the anxiety- 
and depression-like behavior and hyperactivity of the HPA axis were determined in nicotine-
treated mice.  
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3. MATERIALS AND METHODS 
 
3.1. Materials 
The selective CRFR agonists used in the experiments were:  
UCN II (Bachem, Switzerland), a selective CRFR2 agonist; 
UCN III (Bachem, Switzerland), a selective CRFR2 agonist. 
The selective CRFR antagonists used in the experiments were:  
Antalarmin (Sigma-Aldrich, UK), a selective CRFR1 antagonist; 
Astressin 2B (Sigma-Aldrich, UK), a selective CRFR2 antagonist. 
Other substances used in experiments were: 
[
3
H]dopamine (Amersham, USA), a tritium-labelled excitatory neurotransmitter; 
Krebs solution: NaCl, KCl, MgSO4, NaHCO3, glucose, KH2PO4 and CaCl2  
(Reanal, Hungary) for incubation and superfusion of the tissues; 
Saline solution (NaCl inj. of 0.9 %, Biogal, Hungary); 
Nicotine solution (1.4-2 mg/kg, Biogal, Hungary); 
Ultima Gold (Perkin Elmer, USA), a scintillation fluid; 
Mixture of 5 % CO2 and 95 % O2 for continuous gassing of the tissues; 
Euthasol (Pentobarbital sodium, CEVA-Phylaxia, Hungary) for general anesthesia of 
the rats; 
Ethyl alcohol, methylene chloride and sulfuric acid of analytical grade (Reanal, 
Hungary) for determination of the plasma corticosterone concentration; 
Ethyl alcohol and sodium hypochlorite (Reanal, Hungary) for cleaning in between the 
experimental sessions. 
           
3.2. Animals 
First, male Wistar rats weighing 150-250 g upon arrival were used (N = 80). The rats 
were housed together and kept in their home cages at a constant temperature on a standard 
illumination schedule with 12-h light and 12-h dark periods (lights on from 6:00). 
Commercial food and tap water were available ad libitum [69]. 
Second, male CFLP mice weighing 24-30 g were used (N = 77). The animals were 
housed in their home cages at constant room temperature (23°C) on a standard illumination 
schedule, with 12-h light and 12-h dark periods (lights on from 6:00 a.m.). Commercial food 
and tap water were available ad libitum [70]. 
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The animals were allowed for 7 days to acclimatize before surgery and they were 
handled daily to minimize the effects of non-specific stress. Although sexually maturized, the 
experimental animals were considered adolescents, since they were about 6-7 weeks old when 
the experiments had started [71]. Pre-adolescence and adolescence are developmental periods 
associated with increased vulnerability for nicotine addiction, and exposure to nicotine during 
these periods may lead to long-lasting changes in behavioral and neuronal plasticity in 
different brain regions, such as the cerebral cortex, hippocampus and striatum [72-73]. During 
the experiments the animals were kept and handled in accordance with the instructions of the 
University of Szeged Ethical Comittee for the Protection of Animals in Research. 
            
3.3. Surgery 
 The rats were implanted with a stainless steel Luer cannula (10 mm long), aimed at the 
right lateral cerebral ventricle under anesthesia with 60 mg/kg pentobarbital sodium.  
The stereotaxic coordinates were 0.2 mm posterior and 1.7 mm lateral to the bregma, 3.7 mm 
deep from the dural surface, according to the stereotaxic atlas of the rat brain [74]. Cannulas 
were secured to the skull with dental cement and acrylate. The rats were allowed for 7 days to 
recover before experiments were started. After the experiments were concluded, 10 μl of 
methylene blue at 1 g/100 ml were injected into the lateral cerebral ventricle of the 
decapitated animals and the position of the cannula was inspected visually. Animals without 
the dye in the lateral cerebral ventricle (8 from 80) were excluded from the final statistical 
analysis. 
The mice were implanted with a polyethylene Luer cannula (6 mm long) aimed at the 
right lateral cerebral ventricle under anesthesia with 60 mg/kg of pentobarbital sodium.  
The stereotaxic coordinates were 0.5 mm posterior and 0.5 mm lateral to the bregma, and  
3 mm deep from the dural surface [75]. Cannulas were secured to the skull with cyanoacrylate 
containing instant glue. The mice were allowed for 7 days to recover after the surgery. After 
the experiments were ended, 2 µl of methylene blue was injected into the lateral cerebral 
ventricle of the decapitated animals to check the permeability and the right position of the 
cannula. Animals without the dye in the lateral cerebral ventricle (5 from 77) were omitted 
from the final statistical analysis.  
 
3.4. Treatment 
The rats were treated intraperitoneally (IP) with 1.4 mg/kg nicotine tartrate or 10 
ml/kg of 0.9% saline solution for 7 days, two times per day (at 8:00 and at 20:00). 
18 
Half of the rats were treated intracerebroventricularly (ICV) with 0.1 µg/2µl antalarmin or 1 
µg/2µl astressin 2B or 2 µl of 0.9% saline solution on the 8th day (after 12 hours following the 
last IP administration). The other half of the animals were treated ICV on the 9
th
 day (after 24 
hours following the last IP administration) based on the same treatment protocol. Hence, rats 
were divided in 6 groups: group 1. saline IP + saline ICV; group 2. saline IP + antalarmin 
ICV; group 3. saline IP + astressin 2B ICV; group 4. nicotine IP + saline ICV; group 5. 
nicotine IP + antalarmin ICV; and group 6. nicotine IP + astressin 2B ICV [69]. 
The mice were treated IP with 2 mg/kg nicotine tartrate or 10 ml/kg saline solution for 
control for 7 days, 4 times per day. Half of the mice were treated ICV on the 8th day  
(12 hours after the last IP treatment), the other half on the 9th day (24 hours after the last IP 
treatment) with 2 µg/2µl UCN II, 2 µg/2µl UCN III or 2 µl of saline solution for control. 
Thus, mice were divided in 6 groups based on the following treatments: 1. saline IP + saline 
ICV, 2. saline IP + UCN II ICV, 3. saline IP + UCN III ICV, 4. nicotine IP + saline ICV, 5. 
nicotine IP + UCN II ICV and 6. nicotine IP + UCN III ICV [70]. 
The doses of nicotine and the schedule of administration chosen were expected to 
produce plasma nicotine levels in rats similar to plasma nicotine levels found in an individual 
who smokes 1-2 packs of cigarettes per day [76].  
 
3.5. In vivo conducta studies 
 Thirty minutes after the ICV injection, the horizontal and vertical locomotor activities 
were recorded in an in vivo conducta system (MDE, Ltd, Germany), which is based on the 
principles of the open-field test and was described in previous studies [77-78]. The apparatus 
was a square open-field black box with a side length of 60 cm, surrounded by a 40 cm high 
wall. The floor of the box was divided in 36 (6×6) small squares. Five by five rows of 
photocell beams allowed a computer-based system to register the behavioral activity of each 
animal.  A 60 W light was situated 1 m above the arena floor. Each animal was carried to the 
experimental room in their home cage and placed in the center of the box with which they 
were familiarized for 5 min. Then the horizontal activity, representing a measure of overall 
activity and arousal, and the vertical activity, representing a measure of exploratory and 
stereotype behavior, were monitorized for 30 minutes. The box was cleaned between sessions 
with 96 % ethyl-alcohol. 
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3.6. In vitro superfusion studies  
After the decapitation of the rats the changes of the dorsal and ventral striatal 
dopamine release were determined by an in vitro superfusion system (MDE, Ltd, Germany) 
described in previous studies [79-82]. The striatum was isolated and dissected in a Petri dish 
filled with ice-cold Krebs solution. The stereotaxic coordinates were 4.0 mm anterior and 1.0 
mm posterior to the bregma, according to the stereotaxic atlas of the rat brain [74].  
The dorsal striatum, including the putamen and the nucleus caudatus, and the ventral striatum, 
including the nucleus accumbens (NAcc), were decapsulated from the surrounding white 
matter and separated from each other. Slices of 300 µM were produced with a McIlwain 
tissue chopper (Campden Instruments Ltd., UK). The slices were incubated for 30 min in 8 ml 
of Krebs solution, submerged in a water bath at 37 °C and gassed through a single-use needle 
with a mixture of 5% CO2 and 95% O2. During the incubation, the slices were labelled with 
15 µmol of [3H]dopamine with a specific activity of 14 Ci/mmol. Two tritiated slices were 
transferred to each of the four cylindrical perspex chambers of the superfusion system. Gold 
electrodes were attached to both halves of the superfusion chambers and connected to an ST-
02 electrical stimulator (MDE, Co. Ltd., Germany). A multichannel peristaltic Gilson 
Minipuls 2 pump (Gilson Inc., USA) was used to maintain a constant superfusion rate of 300 
µl/min. The slices were superfused for 30 min to allow tissue equilibrium, and the 
superfusates were collected in Eppendorf tubes by a multichannel fraction collector Gilson FC 
203B (Gilson Inc., USA). After 2 minutes electrical stimulation consisting of square-wave 
impulses (intensity: 10 mA, voltage: 100 V, pulse length: 5 ms, frequency: 10 Hz) was 
delivered to each of the four chambers lasting two minutes. The sample collecting lasted 32 
minutes (2 minutes for each sample) and the peak of the fractional release was observed at 14 
minutes. The remnants of slices were solubilized in 200 ml of Krebs solution, using an 
ultrasonic homogenizer Branson Sonifier 250 (Labequip Ltd., Canada). The radioactivity in 
the fractions and the homogenized tissue samples was measured with a liquid scintillation 
spectrometer (Tri-carb 2100TR, Packard Inc., USA) after the addition of 3 ml of scintillation 
fluid. The fractional release was calculated as a percentage of the radioactivity present in each 
collected sample compared to the total radioactivity of the correspondent tissue.  
    
3.7. Elevated plus-maze test 
Thirty minutes after the ICV treatment, the animals were evaluated in an elevated 
plus-maze test, validated by Lister and Rodgers to investigate anxiety-like behavior [83-84]. 
The apparatus consists of a plus-shaped wooden platform elevated at 40 cm from the floor, 
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made-up by four opposing arms of 30 cm × 5 cm. Two of the opposing arms are enclosed by 
15 cm-high side and end walls (closed arms), whereas the other two arms have no walls (open 
arms). The principle of the test is that open arms are more fear-provoking and the ratio of the 
times spent in open vs. closed arms, or the ratio of the entries into open vs. closed arms, 
reflects the relative safety of closed arms, as compared with the relative danger of open arms.  
Each mouse was placed in the central area of 5 cm × 5 cm of the maze, facing one of the open 
arms. For a 5 minutes period the following parameters were recorded by an observer sitting at 
100 cm distance from the center of the plus-maze: a. the percentage of the number of entries 
into the open arms relative to the total number of entries, b. the percentage of the time spent in 
the open arms relative to the total time and c. the total number of entries into the open and the 
closed arms. Entry into an arm was defined as the entry of all four feet of the animal into that 
arm. The apparatus was cleaned up with sodium hypochlorite solution between the subjects. 
       
3.8. Forced swim test 
In parallel, the animals were evaluated in a forced swim test, invented by Porsolt et al. 
to investigate depression-like behavior [85]. The apparatus consists of a plexiglass cylinder of 
40 cm height and 12 cm diameter positioned on a table. The cylinder was half-filled with 
water maintained at 25±1 °C. The principle of the test is that in such a situation, from which 
they cannot escape, animals rapidly became immobile, that is, ﬂoating in an upright position 
and making only small movements to keep their heads above water. Meanwhile their attempt 
to escape the cylinder by climbing or swimming may decrease or cease eventually.  
Each mouse was dropped individually into the water. For a 5 minutes period the following 
parameters were recorded by an observer sitting at 100 cm distance from the table: a. the 
climbing activity (the time that animals spent with climbing the walls, in their attempt to 
escape the cylinder), b. the swimming activity (the time that animals spent with swimming in 
the water, in their attempt to remain at the surface) and c. the time of immobility (the time that 
animals spent in an upright position on the surface with its front paws together). A 5 second 
period was considered a time unit, thus the climbing and the swimming activities and the time 
of immobility were expressed in time units. The water from the apparatus was changed 
between the subjects. 
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3.9. Chemo-fluorescent assay 
After the decapitation of the mice, the trunk blood was collected for determination of 
plasma corticosterone concentration by a chemo-fluorescent assay that was described by 
Zenker and Bernstein and later modified by Purves and Sirett [86-87]. According to this 
method, the trunk blood was collected into heparinized tubes and centrifuged for 10 min at 
3000 rpm for determination of the plasma corticosterone levels. Two hundred ml aliquots of 
the medium were transferred to centrifuge tubes. A reagent blank of 200 µl of distilled water 
and 2 corticosterone standards of the same volume containing 25 µg or 50 µg, respectively, 
were prepared. Five ml of methylene chloride was delivered with an automatic pipette to each 
tube and rocked for 30 min to allow complete extraction of corticosterone by the solvent.  
The extract is centrifuged for 10 min at 3000 rpm. In order to eliminate any aqueous phase, 
approximately 3.2 ml of the lower hydrophobic phase was aspired with a glass syringe then 
transferred into another centrifuge tube. Five ml of fluorescent reagent (stable mixture of 2.4 
volumes of sulfuric acid and 1.0 volume of 50 % v/v aqueous ethyl-alcohol) was added to the 
extract. The tubes were shaken vigorously for 15 min, centrifuged at 3000 rpm for 10 min and 
was allowed to stand at room temperature for 2 hours, which permitted the maximum 
development of fluorescence from corticosterone. Emission intensity was measured from the 
lower sulfuric acid layer with Hitachi 204-A fluorescent spectrophotometer at 456 nm 
extinction and 515 emission wave-length. The concentration of corticosterone of the samples 
was calculated from the values of the standards and expressed in µg/100 ml. 
 
3.10. Statistical analysis 
Statistical analysis of the results was performed by analysis of variance (Prism 7 
Statistics, GraphPad Inc., USA). The differences between groups were determined by  
two-way ANOVA followed by Tukey’s test for pairwise comparisons when prerequisites 
were fulfilled. A probability level of 0.05 or less was accepted as indicating a statistically 
significant difference. 
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4. RESULTS 
 
4.1. After 12 hours of nicotine withdrawal 
 On the 8
th
 day, the horizontal and vertical locomotor activity increased significantly in 
nicotine-treated rats, compared with the saline-treated rats (Figure 13). In parallel, the dorsal 
and ventral striatal dopamine release increased significantly in nicotine-treated group, 
compared with the saline-treated group (Figure 14). All the changes observed on the 8
th
 day 
were reduced significantly after treatment with antalarmin, but not astressin 2B [69] 
(Figures 13-14). 
On the 8th day, the time spent in the open arms and the number of entries into the 
open arms increased remarakably, with the first parameter increasing significantly, but the 
total number of entries did not change significantly in nicotine-treated mice, compared to the 
saline-treated ones. The first two parameters increased further after treatment with UCN II or 
UCN III in the nicotine-treated groups, but only the time spent in the open arms was increased 
significantly (Figure 15). The swimming and the climbing activity decreased significantly in 
nicotine-treated mice, compared to the saline-treated ones, but the time spent immobile was 
not altered. After treatment with UCN II and UCN III the swimming and the climbing activity 
decreased further in the nicotine-treated groups, both parameters decreasing significantly, but 
the time of immobilization was not altered (Figure 15). The plasma corticosterone 
concentration was elevated considerably, but insignificantly in the nicotine-treated group, 
compared to the saline-treated one, and this elevation of the plasma corticosterone level was 
reduced significantly after treatment with UCN II and UCN III [70] (Figure 16). 
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Figure 13. The changes of horizontal (A) and vertical locomotor activity (B) observed after 
12 hours following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p< 0.05 and indicated with * for 
nicotine IP + saline ICV vs. saline IP + saline ICV and with # for nicotine IP + 
antalarmin ICV vs. nicotine IP + saline ICV 
24 
 A. 
0
1
2
3
4
5
6
7
8
9
10
On the 8th day
fr
ac
ti
o
n
al
 r
el
ea
se
  
(%
)
Dorsal striatal dopamine release
(after 12 hours)
saline ip + saline icv (6)
saline ip + antalarmin icv (6)
saline ip + astressin2B icv (6)
nicotine ip + saline icv (6)
nicotine ip + antalarmin icv (6)
nicotine ip + astressin2B icv (6)
*
#
 
 B. 
  
0
1
2
3
4
5
6
7
8
9
10
On the 8th day
fr
ac
ti
o
n
al
 r
el
ea
se
 (
%
)
Ventral striatal dopamine release
(after 12 hours)
saline ip + saline icv (6)
saline ip + antalarmin icv (6)
saline ip + astressin2B icv (6)
nicotine ip + saline icv (6)
nicotine ip + antalarmin icv (6)
nicotine ip + astressin2B icv (6)
*
#
 
Figure 14. The changes of dorsal (A) and ventral striatal dopamine release (B) observed after 
12 hours following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p< 0.05 and indicated with * for 
nicotine IP + saline ICV vs. saline IP + saline ICV and with # for nicotine IP + 
antalarmin ICV vs. nicotine IP + saline ICV 
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 Figure 15. The signs of anxiety (A) and depression (B) observed after 12 hours 
following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p < 0.05 
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Figure 16. The changes of plasma corticosterone concentration measured after 12 hours 
following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p < 0.05 
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4.2. After 24 hours of nicotine withdrawal 
 On the 9
th
 day, significant increases of the horizontal locomotor activity and dorsal 
striatal dopamine release were observed in the nicotine-treated group, compared with the 
saline-treated group (Figures 17-18). In contrast, the vertical locomotor activity and the 
ventral striatal dopamine release were decreased significantly in the nicotine-treated rats, 
compared with the saline-treated rats (Figures 17-18). All the changes described on the 9
th
 
day were reversed completely after treatment with antalarmin, but not astressin 2B [69] 
(Figures 17-18). 
 On the 9th day, the number of entries into the open arms and the time spent in the 
open arms decreased significantly in nicotine-treated mice, compared to the saline-treated 
ones, but the total number of entries was not affected significantly in the nicotine-treated 
group. The decreasing effects were inverted after treatment with UCN II and UCN III, but 
only the number of entries was increased significantly, and the total number of entries was not 
affected in the nicotine-treated groups (Figure 19). The swimming and the climbing activity 
decreased significantly, and the time of immobilization increased significantly as well, in 
nicotine-treated mice, compared to the saline-treated ones. After treatment with UCN II or 
UCN III the time spent with climbing and swimming was enhanced significantly and the time 
spent immobile was reduced significantly in the nicotine-treated groups (Figure 19). The 
plasma corticosterone concentration was augmented remarkably and significantly in the 
nicotine-treated group, compared to the saline-treated one, but this augmentation of the 
plasma corticosterone level was abolished completely after treatment with UCN II and UCN 
III [70] (Figure 20). 
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Figure 17. The changes of horizontal (A) and vertical locomotor activity (B) observed after 
24 hours following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p< 0.05 and indicated with * for 
nicotine IP + saline ICV vs. saline IP + saline ICV and with # for nicotine IP + 
antalarmin ICV vs. nicotine IP + saline ICV 
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Figure 18. The changes of dorsal (A) and ventral striatal dopamine release (B) observed after 
24 hours following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p< 0.05 and indicated with * for 
nicotine IP + saline ICV vs. saline IP + saline ICV and with # for nicotine IP + 
antalarmin ICV vs. nicotine IP + saline ICV 
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Figure 19. The signs of anxiety (A) and depression (B) observed after 24 hours following the 
last IP administration of nicotine or saline 
Statistically significant difference was accepted for p < 0.05 
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Figure 20. The changes of plasma corticosterone concentration measured after 24 hours 
following the last IP administration of nicotine or saline 
Statistically significant difference was accepted for p < 0.05 
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5. DISCUSSION 
 
5.1. Nicotine addiction: definition 
 Drug addiction, also known as substance dependence, is a chronically relapsing 
disorder that is characterized by the compulsion to seek and take the drug, the loss of control 
in limiting intake, and the emergence of a negative emotional state when access to the drug is 
prevented [88]. According to the latest, fifth edition of Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5), nicotine addiction or nicotine dependence is described as 
”tobacco use disorder” [89]. DSM-5 defines 3 criteria with 15 sub-features and 4 specifiers to 
set up the clinical diagnosis of tobacco use disorder [90]. For the positive diagnosis one must 
use tobacco for over one year and at least two of the sub-features should be met [90].  
Drug addiction (including nicotine addiction) has been further conceptualized as a dynamic, 
evolving disorder that consists of three stages: binge/intoxication, withdrawal/negative affect 
and preoccupation/anticipation or craving [88] (Figure 21). 
 
 
 
Figure 21. The stages of nicotine addiction [9] 
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5.2. Nicotine addiction: binge/intoxication 
 Acute use of nicotine increases the release of the striatal dopamine that is associated 
with a sensation of reward, euphoria and locomotor hyperactivity in rats [91-92]. The search 
for the sensation of reward and euphoria represents the positive reinforcement that leads to 
nicotine addiction [93]. Chronic use of nicotine also increases the striatal dopamine release, 
although its impact on the locomotor activity depends upon the dose of the drug and the 
schedule of administration [94-95]. Usually, continuous infusion of nicotine several times a 
day may induce tolerance, while repetitive injection once a day may produce sensitization to 
the effects of nicotine [96-97]. Nicotine also augments glutamate release, which stimulates the 
release of dopamine, and GABA release, which inhibits the release of dopamine. With  
long-term exposure to nicotine, some nAChRs become desensitized, but some do not [65, 76]. 
As a result, GABAergic inhibitory tone diminishes, while glutamatergic excitation continues, 
thereby increasing excitation of dopaminergic neurons and enhancing responsiveness to 
nicotine [65, 76] (Figure 22). 
This stage is mediated by the nigrostriatal and mesolimbic pathways [96-97].  
The nigrostriatal pathway originates in the dopaminergic neurons located in the substantia 
nigra and terminates in the putamen and nucleus caudatus which together constitute the dorsal 
striatum [96-97]. The mesolimbic pathway arises from the dopaminergic neurons situated in 
the ventral tegmental area and projects to the NAcc that represents the ventral striatum [96-
97]. Classically, the nigrostriatal pathway controls motor behavior, posture and learning of 
motor programs and habits, whereas the mesolimbic pathway contributes to motor behavior 
by mediation of reward, emotion and motivation [98]. Nevertheless, manipulations of 
dopamine release in the dorsal and ventral striatum affect motor behavior in distinct, but 
parallel ways, which depend upon the nature of the cortical and limbic input to these brain 
structures [98] (Figure 24). 
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Figure 22. Clinical signs (A) and anatomical/pharmacological backround (B) of chronic 
nicotine use [99] 
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Figure 23. Clinical signs (A) and anatomical/pharmacological backround (B) of acute 
nicotine withdrawal [99] 
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5.3. Nicotine addiction: withdrawal/negative affect 
 Acute withdrawal following chronic administration of nicotine causes a nicotine 
withdrawal syndrome that starts promptly within few hours, peaks around 24 hours, and lasts 
a few days following cessation of chronic nicotine administration [100]. The nicotine 
withdrawal syndrome in rats consists of  a somatic component, characterized by locomotor 
hypoactivity, increased appetite and weight gain and an affective component, represented by 
anxiety, depression and reward deficit [101]. The somatic symptoms in humans include 
bradycardia, gastrointestinal discomfort and increased appetite; in rodents they correspond to 
locomotor hypoactivity, increased appetite and weight gain and stereotype behavior [66-67, 
101]. The affective symptoms in humans incorporate dysphoria, anxiety, depression, 
irritability and difficulty concentrating; in rodents they correlate with anhedonia, anxiety- and 
depression-like behavior [66-67, 101] (Figure 23). 
 This stage is mediated by the extended amygdala, a functional unit that consists of 
three anatomically distinct structures: the CeA, the BNST and the shell part of NAcc [93]. 
The extended amygdala can be regarded as an interface between stress systems and reward 
systems, the activation of which produces a negative emotional state that is mediated by CRF, 
NA and dynorphin [93]. The avoidance of the dysphoria, anxiety and depression represents 
the negative reinforcement that maintains nicotine addiction [93] (Figure 24). 
 
5.4. Nicotine addiction: preoccupation/anticipation or craving 
 Some of the affective symptoms, such as anxiety and depression, may persist during 
chronic nicotine withdrawal leading to the third stage of nicotine addiction, characterized by 
preoccupation/anticipation or craving [93]. The craving for drug use is hypothesized to play a 
key element in relapse in humans, thus leading to the so called “chronic relapsing disorder” 
[93]. Exposure to stressors is one of the leading causes of nicotine relapse that implicates the 
activation of the anti-reward and stress systems for months or years after quitting the drug use 
[58-59]. Nevertheless, the senzation of craving does not always correlate with relapse and is 
difficult to measure clinically [93]. 
 The most important brain regions involved in this stage are the basolateral amygdala 
and the hippocampus which mediate the conditioned reinforcement and processing of 
contextual information, respectively [93]. The executive control depends on the prefrontal 
cortex which integrates the signals received from the orbital, medial and cingulate cortex 
which, in turn, mediate the subjective feeling of craving itself [93]. The major 
neurotransmitter involved in this stage is glutamate [93] (Figure 24). 
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Figure 24. Clinical stages of nicotine addiction: binge/intoxication (A), withdrawal/negative 
affect (B) and preoccupation/anticipation or craving (C) [93] 
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5.5. The effects of chronic nicotine treatment 
 In concordance with the features of the stage of binge/intoxication, in rats exposed to 7 
days of nicotine treatment (after 12 hours following the last nicotine administration)  
we observed increases in horizontal and vertical locomotor activity along with increases in the 
dorsal and ventral striatal dopamine release. This finding is in line with previous studies 
which reported locomotor hyperactivity on the 4th and the 10th day of a chronic nicotine 
exposure [94-95]. The authors of these studies suggested that nicotine-treated rats develop 
locomotor hyperactivity in response to nicotine, initially due to increases of both the density 
of dopamine receptors (D1 and D2) and dopamine concentration, and lately due to dopamine 
receptor supersensitivity in the striatum [102]. The interpretation of the behavioral changes 
observed following chronic nicotine treatment is somewhat complicated by the observation 
that the impact of chronic nicotine exposure on locomotion depend upon sex, age, and 
housing conditions [103-107]. Female animals are less sensitive to the acute and chronic 
effects of nicotine, but more sensitive to the impact of acute nicotine withdrawal, including 
the neuroendocrine and behavioral stress responses, when compared to males [103, 105, 108-
110]. As regards the locomotor actions of nicotine in male and female Long-Evans and 
Sprague-Dawley rats, the horizontal activity was more enhanced in Long-Evans females, and 
the vertical activity was unaltered in Sprague-Dawley males [103]. Also, younger animals 
exhibit increased sensitivity to the positive, rewarding effects of nicotine and reduced 
sensitivity to the negative, aversive effects of nicotine withdrawal which may contribute to the 
higher risk to develop nicotine addiction in adolescents, when compared to adults [73, 107]. 
As regards the locomotor actions of nicotine, during chronic nicotine administration 
adolescent males exhibited a greater locomotor activity, when compared to adult males or 
adolescent females [106]. During nicotine cessation, nicotine-treated adolescent males 
continued to exhibit greater locomotor activity than saline-treated animals [106]. Another 
possible factor influencing the results is the housing condition [104]. In saline-treated rats, 
group housing decreased the horizontal and vertical activity and the center time, a measure of 
anxiety with effects ocurring sooner in females [104]. For males, nicotine altered both the 
horizontal and vertical activity, increasing these variables for group-housed males, but 
decreasing them for individually housed males [104]. For females, nicotine altered only the 
center time, reducing this measure of anxiety for group-housed females [104]. During nicotine 
cessation, housing effects appeared more robustly in males and continued in females [104]. 
Thus, investigation of additional factors, such as sex, age and housing conditions is desirable, 
but would require more complex experimental design and statistical analysis. 
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In mice exposed to 7 days of nicotine treatment (after 12 hours following the last 
nicotine administration) we observed signs of anxiolysis, as mice treated with nicotine spent 
more time in the open arms of the elevated plus-maze than those treated with saline.  
This result is supported by a previous study which reported that subchronic administration of 
nicotine (0.1 mg/kg subcutaneously = SC for 6 days) produces anxiolytic effect in mice [111] 
and it is opposed by other studies which referred that subchronic (0.3 mg/kg/day nicotine SC 
for 4 days) or chronic administration (25 mg/kg/day nicotine via minipump for 14 days) of 
nicotine in higher doses than 0.1 mg/kg induces anxiogenic behavior in mice [112-113].  
We also observed signs of depression, as mice treated with nicotine spent less time with 
swimming and climbing in the water than those treated with saline. This result is underlined 
by previous studies according to which repeated IP nicotine treatment (0.3 mg/kg/day IP for 4 
days) produces depression-like behavior [114-115]. Although in our study despite of the 
significant decrease in the time spent with swimming and climbing, there was no significant 
difference in the time spent immobile - this being a more typical sign of depression in the 
forced swim test - in nicotine-treated animals, when compared to the saline-treated animals. 
Therefore, our results could be rather interpreted as a consequence of the locomotor 
suppressive effect exerted by nicotine [103-104], than an apparently coexisting anxiolytic and 
depressive behavior. In addition, the behavioral changes described in mice were not 
accompanied by significant elevation of the plasma corticosterone concentration.  
 
5.6. The effects of acute nicotine withdrawal  
 In accordance with the features of the stage of withdrawal/negative affect, in rats 
exposed to 1 day of nicotine withdrawal (after 24 hours following the last nicotine 
administration) we expected a decrease of general locomotor activity and a decrease of global 
striatal dopamine release, which were actually assessed in a previous study following 14 days 
of nicotine exposure and 24 hours of nicotine withdrawal [100]. Interestingly, in the present 
experiments only the vertical locomotor activity and the ventral striatal dopamine release 
were decreased, while the horizontal locomotor activity and the dorsal striatal dopamine 
release remained increased following acute nicotine withdrawal. The explanation of this 
finding might be offered by the authors of this previous study, who showed a reduction of the 
maximum number of D2 receptor sites in the NAcc, but found no alteration of the density and 
binding affinity of dopamine receptors (D1 and D2) in the putamen and nucleus caudatus 
[102]. Additionally, the dose and the schedule of the nicotine exposure may also contribute to 
the difference between the previous and present results. Thus, while tolerance is more likely 
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to be induced by continuous infusion of nicotine (performed in the previous study), behavioral 
sensitization is frequently induced by intermittent injection of nicotine (performed in the 
present study) [96-97]. Nonetheless, continuous exposure to nicotine at doses that result in 
tolerance to the nicotine-induced sensitization, induces itself a sensitization that is demasked 
as the tolerance wears off. Hereby tolerance and sensitization must be regarded as two distinct 
adaptive changes that usually require different conditions, but may also occur following the 
same dose and schedule of chronic nicotine exposure [96-97]. Consequently, during acute 
nicotine withdrawal these competing phenomena could be manifested differently between the 
two subdivisions of the striatum and accordingly, the two aspects of locomotor activity [96-
97]. The discrepancies between the behavioral and neurochemical parameters observed 
following acute nicotine withdrawal is underlined by the differential nicotinic regulation of 
the nigrostriatal and mesolimbic dopaminergic pathways [116-117]. For example, there are 
clear differences in the distribution and characteristics of various nAChR subtypes between 
the dorsal and ventral striatum [116-119]. Acute nicotine exposure increases directly the 
striatal dopamine neurotransmission via presynaptic nAChRs that are α6β2 and/or α4β2 
subunit-containing, depending on the brain region [116-117]. The nAChR subtypes that 
regulate dopaminergic neurotransmission depend critically upon α5 subunits (non-α6 
nAChRs) in the dorsal striatum and upon α6 subunits (α6 nAChRs) in the ventral striatum 
[119]. Chronic nicotine exposure produces no change in the control of dopamine release by 
α6 relative to non-α6 nAChRs in the putamen and nucleus caudatus, but it induces a 
downregulation of the α6 nAChRs and an upregulation of non-α6 nAChRs in the NAcc [118]. 
In addition, nicotine modulates the release of dopamine indirectly, through the release of 
glutamate and GABA following activation of post-synaptic α7 containing nAChRs [116-119]. 
Furthermore, there are also differences in the regulation of dopamine release by different 
nicotinic agonists [116-119]. For instance, nicotine stimulates especially the mesolimbic 
dopaminergic pathway, in contrast, epibatidine, the most potent nAChR agonist known to 
date, stimulates preferentially the nigrostriatal pathway [116-117]. The difference in the dose-
response curves of the two nicotinic agonists regarding the dorsal and ventral striatal 
dopamine release suggests different abilities for downregulation and desensitization of the 
nAChRs found in these brain regions [116-117]. This imbalance in the distribution and the 
function of nAChRs between the dorsal and ventral striatum might explain the dopamine 
dysregulation assessed during acute nicotine withdrawal. 
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Mice exposed to 1 day of nicotine withdrawal (after 24 hours following the last 
nicotine administration) exhibited signs of anxiety, since the number of entries into the open 
arms and the time spent in the open arms of the plus-maze decreased in the nicotine-treated 
group, compared to the saline-treated one. This result is in agreement with previous studies, 
which showed that acute withdrawal following chronic administration of nicotine (1 day of 
withdrawal following 0.1 mg/kg/day IP treatment for 14 days or 12-24-48 mg/kg/day 
treatment via minipump for 14 days) precipitates anxiety-like behavior in mice tested in light-
dark box or elevated plus-maze. Mice exposed to 1 day of nicotine withdrawal expressed 
signs of depression as well, since the time spent with swimming and climbing in the water 
increased in parallel with the time of immobilization in the nicotine-treated group, compared 
with the saline-treated one. This result coincides with that of a previous study using a similar 
treatment protocol (2 mg/kg nicotine IP, 4 times/day), following which signs of depression 
were indicated during acute and chronic nicotine withdrawal in mice investigated in forced 
swim test [120]. In concordance with these behavioral changes, significant elevation of the 
plasma corticosterone concentration, reflecting the hyperactivity of the HPA axis, was 
observed on the 9
th
 day of our study. Indeed, hyperactivity of the HPA axis is associated 
frequently with nicotine withdrawal syndrome [121-122] and generally with states of anxiety 
and depression [123-124]. 
ICV injection of UCN II or UCN III performed in the morning of the 9
th
 day increased 
the open-arm activity that was previously decreased by acute nicotine withdrawal. 
Concomitently, ICV injection of UCN II or UCN III reversed the swimming and the climbing 
activity and the immobility of mice, which were increased and decreased, respectively, by 
acute nicotine withdrawal. As a matter of fact, the anxiolytic and the antidepressant effects of 
the urocortins validated in the present study have been already indicated by previous studies 
using the same methods [35-37]. Additionally, a single administration of UCN II or UCN III 
attenuated the levels of the plasma corticosterone which were remarkably and significantly 
augmented on the 9
th
 day in nicotine-treated animals. 
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6. CONCLUSION 
 
 Taken together, this study demonstrate that both selective CRFR1 antagonists, such as 
antalarmin and selective CRFR2 agonists, such as UCN II and UCN III could be promising 
candidates as potential therapy in nicotine addiction.  
On the one hand, we demonstraded that antalarmin reversed the alterations of the 
dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity 
which characterize the binge/intoxication phase of nicotine addiction. Actually, these 
experiments are the first to elucidate that both the rewarding, positive reinforcing effects of 
chronic nicotine treatment and the aversive, negative effects of acute nicotine withdrawal can 
be attenuated by administration of selective CRFR1 antagonists, such as antalarmin. 
On the other hand, we demonstrated that UCN II and UCN III reduce the anxiety- and 
depression-like behavior and hyperactivity of the HPA axis that arise during the 
withdrawal/negative affect phase of nicotine addiction and may persist during the 
preoccupation/anticipation phase as well. Consequently, these are the first experiments to 
demonstrate that administration of selective CRFR2 agonists, such as UCN II and UCN III 
ameliorate the anxiety- and depression-like signs developed following chronic nicotine 
treatment and the consequent acute nicotine withdrawal, and the hyperactivity of the HPA 
axis that is associated to them. 
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